A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05593094. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors
Study identification
- NCT ID
- NCT05593094
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Interventions
- ZN-A-1041 Drug
- ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b Drug
- ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c Drug
- ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b Drug
- ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c Drug
- ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b Drug
- ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2, 2020
- Primary completion
- Jul 30, 2027
- Completion
- Jul 30, 2027
- Last update posted
- Feb 24, 2026
2020 – 2027
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Clinical Research Center, Inc.;Hematology Oncology Physicians - Aoa | Tucson | Arizona | 85712 | — |
| TOI Clinical Research | Cerritos | California | 90703-2684 | — |
| UCSF Helen Diller Family CCC | San Francisco | California | 94158 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Hospital | Ann Arbor | Michigan | 48109 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Duke University School of Medicine | Durham | North Carolina | 27710 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030-4000 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05593094, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05593094 live on ClinicalTrials.gov.